Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,issuanceOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2021) 4","Short Ratio (Jul 14, 2021) 4","Short % of Float (Jul 14, 2021) 4","Short % of Shares Outstanding (Jul 14, 2021) 4","Shares Short (prior month Jun 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,DXCM,1978500000.0,96705904,129100000,,76700000,,62900000,187000000,417100000,101000000,101000000,,-25200000,,,,13800000,595100000,494100000,178000000,-24300000,,62900000,62900000,2193600000.0,2506200000.0,1997600000.0,30900000.0,4503800000.0,100000.0,-98900000.0,30300000.0,19100000.0,-97200000.0,239700000.0,1158800000.0,600700000.0,216400000.0,2800000.0,770800000.0,3474200000.0,1426100000.0,483500000.0,1710700000.0,319300000.0,165900000.0,468400000.0,-28100000.0,363200000.0,-400000.0,10300000.0,424900000.0,500000.0,61600000.0,23500000.0,-4000000.0,-29500000.0,-40000000.0,-400000.0,62500000.0,-101200000.0,,2873500000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"DexCom, Inc.",False,False,NMS,534.76,1630506659,5.340027,531.9,536.87,526.94,114912,REGULAR,0,2,1.008656,526.94 - 536.87,529.42,535.54,536.26,9,10,finmb_114039,"DexCom, Inc.",NasdaqGS,USD,693471,429616,229.13,0.7496973,305.63 - 536.87,-2.1099854,-0.003930161,305.63,536.87,1619726400,1635159540,1635508800,102.73968,5.205,3.33,2.47,216.50203,19.681,486.99554,47.764465,0.09807988,410.92044,123.83957,0.30137116,51714449408,160.5886,27.171385,15,America/New_York,EDT,-14400000,0.78,,,536.87,305.63,487.0,410.92,693.47k,429.62k,96.71M,,96.19M,0.52%,98.52%,4.31M,5.4,5.02%,4.46%,3.82M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",24.45%,15.90%,5.37%,31.66%,2.17B,22.54,31.70%,1.28B,415.8M,530.6M,5.20,35.90%,2.58B,26.72,1.89B,94.81,5.78,19.68,409M,-115.35M,Value,92121,Healthcare,5500,4,4,"DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.",San Diego,858 200 0200,CA,7,1609372800,1625097600,10,United States,http://www.dexcom.com,86400,8,6340 Sequence Drive,Diagnostics & Research
t-1,DXCM,1884300000.0,96705904,109400000,,21200000,,40300000,188600000,343900000,45900000,45900000,,-24800000,,,,-19100000,505000000,459100000,161100000,-24700000,,40300000,40300000,2162000000.0,2486600000.0,1903200000.0,33700000.0,4389800000.0,100000.0,-161800000.0,28200000.0,18900000.0,-97100000.0,237100000.0,733800000.0,604100000.0,216700000.0,2900000.0,688700000.0,3445100000.0,1898800000.0,443400000.0,1688800000.0,289700000.0,152200000.0,-12000000.0,31100000.0,-112200000.0,800000.0,-52500000.0,-84000000.0,-400000.0,27800000.0,20900000.0,-500000.0,-55000000.0,-14900000.0,-7900000.0,57900000.0,-99700000.0,8700000.0,2841000000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"DexCom, Inc.",False,False,NMS,534.76,1630506659,5.340027,531.9,536.87,526.94,114912,REGULAR,0,2,1.008656,526.94 - 536.87,529.42,535.54,536.26,9,10,finmb_114039,"DexCom, Inc.",NasdaqGS,USD,693471,429616,229.13,0.7496973,305.63 - 536.87,-2.1099854,-0.003930161,305.63,536.87,1619726400,1635159540,1635508800,102.73968,5.205,3.33,2.47,216.50203,19.681,486.99554,47.764465,0.09807988,410.92044,123.83957,0.30137116,51714449408,160.5886,27.171385,15,America/New_York,EDT,-14400000,0.78,,,536.87,305.63,487.0,410.92,693.47k,429.62k,96.71M,,96.19M,0.52%,98.52%,4.31M,5.4,5.02%,4.46%,3.82M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",24.45%,15.90%,5.37%,31.66%,2.17B,22.54,31.70%,1.28B,415.8M,530.6M,5.20,35.90%,2.58B,26.72,1.89B,94.81,5.78,19.68,409M,-115.35M,Value,92121,Healthcare,5500,4,4,"DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.",San Diego,858 200 0200,CA,7,1609372800,1625097600,10,United States,http://www.dexcom.com,86400,8,6340 Sequence Drive,Diagnostics & Research
t-2,DXCM,1807200000.0,96705904,119200000,,81300000,,355200000,175900000,399100000,104000000,104000000,,-24600000,,,,-273900000,568900000,464900000,169800000,-22700000,,355200000,355200000,2125300000.0,2464000000.0,1826500000.0,29200000.0,4290500000.0,100000.0,-202100000.0,26900000.0,19300000.0,-96800000.0,237800000.0,817600000.0,614100000.0,216400000.0,3200000.0,608600000.0,3424800000.0,1890100000.0,428500000.0,1667200000.0,234700000.0,163300000.0,36900000.0,69800000.0,-24000000.0,-4900000.0,31700000.0,144400000.0,1300000.0,172000000.0,20400000.0,-700000.0,-33600000.0,-58500000.0,-4900000.0,-213000000.0,-60200000.0,8700000.0,2810700000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"DexCom, Inc.",False,False,NMS,534.76,1630506659,5.340027,531.9,536.87,526.94,114912,REGULAR,0,2,1.008656,526.94 - 536.87,529.42,535.54,536.26,9,10,finmb_114039,"DexCom, Inc.",NasdaqGS,USD,693471,429616,229.13,0.7496973,305.63 - 536.87,-2.1099854,-0.003930161,305.63,536.87,1619726400,1635159540,1635508800,102.73968,5.205,3.33,2.47,216.50203,19.681,486.99554,47.764465,0.09807988,410.92044,123.83957,0.30137116,51714449408,160.5886,27.171385,15,America/New_York,EDT,-14400000,0.78,,,536.87,305.63,487.0,410.92,693.47k,429.62k,96.71M,,96.19M,0.52%,98.52%,4.31M,5.4,5.02%,4.46%,3.82M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",24.45%,15.90%,5.37%,31.66%,2.17B,22.54,31.70%,1.28B,415.8M,530.6M,5.20,35.90%,2.58B,26.72,1.89B,94.81,5.78,19.68,409M,-115.35M,Value,92121,Healthcare,5500,4,4,"DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.",San Diego,858 200 0200,CA,7,1609372800,1625097600,10,United States,http://www.dexcom.com,86400,8,6340 Sequence Drive,Diagnostics & Research
t-3,DXCM,1480300000.0,96705904,87700000,,75100000,,72200000,158600000,340400000,94100000,94100000,,-24400000,,,,2900000,500900000,406800000,160500000,-19000000,,72200000,72200000,2153700000.0,2333900000.0,1499300000.0,32600000.0,3833200000.0,100000.0,-557300000.0,24800000.0,19000000.0,-97200000.0,21000000.0,673500000.0,506400000.0,,2800000.0,556100000.0,3237100000.0,1930300000.0,370000000.0,1645800000.0,200700000.0,147600000.0,45900000.0,71100000.0,-9300000.0,4500000.0,39800000.0,143800000.0,1000000.0,147600000.0,18400000.0,-7800000.0,-35400000.0,-73400000.0,-4100000.0,54900000.0,-47400000.0,8600000.0,2730700000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"DexCom, Inc.",False,False,NMS,534.76,1630506659,5.340027,531.9,536.87,526.94,114912,REGULAR,0,2,1.008656,526.94 - 536.87,529.42,535.54,536.26,9,10,finmb_114039,"DexCom, Inc.",NasdaqGS,USD,693471,429616,229.13,0.7496973,305.63 - 536.87,-2.1099854,-0.003930161,305.63,536.87,1619726400,1635159540,1635508800,102.73968,5.205,3.33,2.47,216.50203,19.681,486.99554,47.764465,0.09807988,410.92044,123.83957,0.30137116,51714449408,160.5886,27.171385,15,America/New_York,EDT,-14400000,0.78,,,536.87,305.63,487.0,410.92,693.47k,429.62k,96.71M,,96.19M,0.52%,98.52%,4.31M,5.4,5.02%,4.46%,3.82M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",24.45%,15.90%,5.37%,31.66%,2.17B,22.54,31.70%,1.28B,415.8M,530.6M,5.20,35.90%,2.58B,26.72,1.89B,94.81,5.78,19.68,409M,-115.35M,Value,92121,Healthcare,5500,4,4,"DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.",San Diego,858 200 0200,CA,7,1609372800,1625097600,10,United States,http://www.dexcom.com,86400,8,6340 Sequence Drive,Diagnostics & Research
